Confo Therapeutics Raises €30m Series A To Drug Difficult Targets

Belgian drug discovery company raises funds to finance development of its platform to discover compounds targeting difficult-to-drug GPCRs and advance lead program to the clinic.

Euro currency
Confo Secures Enough Funds To Early 2022

Confo Therapeutics, the Ghent-based drug discovery company that uses single domain antibody fragments derived from camelid antibodies, has raised €30m in a Series A round. The funds will be used to accelerate its proprietary drug discovery activities and advance its pipeline of GPCR-modulating compounds to create drug candidates for clinical trials.

“The €30m will get the lead program to Phase I and continue to feed the pipeline to deliver clinical candidates...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip